The Effect of Neoadjuvant Chemotherapy on Physical Functions

NCT ID: NCT06986005

Last Updated: 2025-05-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

46 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-01-08

Study Completion Date

2025-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this observational study was to investigate the effect of neoadjuvant chemotherapy on physical functioning in individuals with breast cancer. The main question that the study aims to answer is how the physical functions of individuals are after neoadjuvant chemotherapy. Demographic information of the participants will be recorded and their physical status will be evaluated by determining body weight and composition, 30-second sit-and-stand test, 9-step stair ascent and descent test, one-leg stand test, upper extremity muscle strength test, lower extremity muscle strength test, tissue dielectric constant measurement, Lower Extremity Functional Scale, Global Physical Activity Questionnaire and Multidimensional Fatigue Rating Scale. In these patients who are planned to receive neoadjuvant chemotherapy for breast cancer, measurements will be made before chemotherapy (T1) and after chemotherapy (T2).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

As a result of the power analysis made from the reference study; when the effect size d=0.8, it was calculated that 80% power could be obtained at 95% confidence level when at least 42 people were included in the study. Considering that a lower effect size can also be obtained, it is planned to complete the study with at least 46 participants by taking 10% more participants.

The data will be analysed with SPSS 25.0 package programme. Continuous variables will be given as mean ± standard deviation and categorical variables as number and percentage. When parametric test assumptions are met, the Significance Test of the Difference Between Two Means will be used to compare independent group differences; when parametric test assumptions are not met, the Mann-Whitney U test will be used to compare independent group differences. In dependent group comparisons, repeated measures analysis of variance will be used when parametric test assumptions are met; Friedman test will be used when parametric test assumptions are not met. In addition, the relationships between continuous variables will be examined by Spearman or Pearson correlation analyses and the differences between categorical variables will be examined by Chi-square analysis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer Neoadjuvant Chemotherapy Neoadjuvant Therapy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Breast cancer patients receiving neoadjuvant chemotherapy

Breast cancer patients who receiving neoadjuvant chemotherapy

No intervention will be performed as part of this study. However, regardless of the study, all participants will receive neoadjuvant chemotherapy.

Intervention Type OTHER

All participants will receive neoadjuvant chemotherapy appropriate to the characteristics of their breast cancer as part of their standard care.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

No intervention will be performed as part of this study. However, regardless of the study, all participants will receive neoadjuvant chemotherapy.

All participants will receive neoadjuvant chemotherapy appropriate to the characteristics of their breast cancer as part of their standard care.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Individuals who are planned to receive neoadjuvant chemotherapy for breast cancer
* Acceptance to participate in the study

Exclusion Criteria

* Previous history of breast cancer
* History of any other cancer
* Refusal to participate in the study
* Refusal to continue working
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

ATİYE KAŞ ÖZDEMİR

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

ATİYE KAŞ ÖZDEMİR

Lecturer PhD.

Responsibility Role SPONSOR_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Pamukkale University

Denizli, , Turkey (Türkiye)

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Atiye KAŞ ÖZDEMİR, Lecturer PhD

Role: CONTACT

+902584151515

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Atiye KAŞ ÖZDEMİR, Lecturer, PhD

Role: primary

+9025841515

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

E-60116787-020-642610

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.